Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical, Inc. (NASDAQ: OM) will release its third-quarter 2021 financial results after the market closes on November 3, 2021. A conference call hosted by CEO Leslie Trigg and CFO Nabeel Ahmed will take place at 2:00 PM PT to discuss these results. The Tablo® Hemodialysis System, which simplifies and reduces costs associated with dialysis, exemplifies Outset's innovation in improving patient care. The system enables dialysis to be provided anywhere with integrated technology for data analytics and water purification.

Outset Medical, Inc. (NASDAQ: OM) announced its participation in two virtual investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference is scheduled for September 9, 2021 at 10:20 a.m. PT, while the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 13, 2021 at 2:00 p.m. PT. Outset's Tablo® Hemodialysis System simplifies dialysis and is FDA-cleared for use in various settings. Live webcasts will be accessible on the Outset website.

Outset Medical, Inc. (Nasdaq: OM) reported a significant financial performance in Q2 2021, with net revenue increasing by 115% to $25.2 million compared to Q2 2020. The company's gross margin improved to 4.2% from (40.6%). Product revenue also surged by 113% to $20.6 million. Operating expenses rose to $31.0 million, and the net loss for the quarter was ($30.2 million), or ($0.66) per share. Outset raised its full-year 2021 revenue guidance to a range of $97 million to $100 million, a projected growth of 94% to 100%.

Outset Medical, Inc. (Nasdaq: OM) has appointed Nabeel Ahmed as the permanent Chief Financial Officer, effective immediately. Ahmed has been serving as the Interim CFO since July 2021 and has been with Outset since May 2020. His diverse experience in finance roles positions him well to lead the company during a pivotal time. Outset is known for its innovative Tablo Hemodialysis System, designed to reduce the cost and complexity of dialysis, facilitating care at various settings.

Outset Medical, Inc. (Nasdaq: OM) will release its second-quarter 2021 financial results on August 5, 2021, after market close. CEO Leslie Trigg and Interim CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Outset Medical is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by integrating water purification and on-demand dialysate production, offering a portable solution for patients and healthcare providers.

Outset Medical (Nasdaq: OM) announces the departure of CFO Rebecca Chambers effective July 16, 2021, with Nabeel Ahmed stepping in as Interim CFO. The company predicts Q2 2021 net revenue between $24.5M to $25.0M, marking a remarkable growth of 109% to 113% year-over-year. Leslie Trigg, CEO, expresses gratitude towards Chambers for her contributions and confidence in Ahmed’s capabilities, given his extensive finance experience. Outset’s technology aims to simplify dialysis, enhancing patient care and operational efficiency.

Outset Medical, Inc. (Nasdaq: OM) has appointed Jean-Olivier Racine as Chief Technology Officer to lead advancements in its dialysis technology. Racine brings over two decades of experience, including roles at Amazon Web Services and expertise in health data services. He aims to enhance patient care and operational efficiency utilizing data-driven innovation. Outset’s FDA-cleared Tablo Hemodialysis System, known for its two-way wireless data transmission, allows real-time data sharing, aiding in analytics and service improvements. Racine's focus will support the unique capabilities of Tablo in transforming dialysis care.

Strive Health, a leader in value-based kidney care, and Outset Medical, Inc. (Nasdaq: OM), a dialysis innovator, have partnered to enhance kidney care. Strive aims to reduce hospitalizations for kidney disease patients using Outset's Tablo Hemodialysis System for home dialysis. The collaboration focuses on delivering high-quality patient care and integrating predictive analytics. Strive recently launched a new dialysis facility in Owensboro, KY, emphasizing holistic kidney management. This partnership aims to improve patient experience and accessibility to home dialysis services.

Satellite Healthcare and Outset Medical (Nasdaq: OM) announced a multi-year sales agreement to enhance home hemodialysis adoption across Satellite Healthcare's dialysis centers. The agreement involves the purchase of Tablo systems for home use and collaboration on educational initiatives to increase patient awareness. Satellite Healthcare aims to lead in at-home dialysis treatment, serving over 8,000 patients annually. Factors such as Medicare Advantage eligibility and increased telehealth usage are expected to drive growth in home dialysis.